SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is a trending topic as anticipation grows for its potential PMDA approval in Japan and its presentation at the J.P. Morgan Healthcare Conference, driving significant community discussion. Investors are actively highlighting the company's innovative Alpha DaRT technology and recent strong clinical data in pancreatic cancer, signaling a potential shift towards increased institutional interest in this transformative oncology player.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to mixed market reactions following its Q4 earnings beat, as the stock experiences a significant dip despite exceeding revenue and EPS estimates. Community discussion centers on concerns over decelerating subscriber growth and conservative 2026 guidance, alongside the ongoing drama and shareholder sentiment surrounding the proposed Warner Bros. acquisition and its impact on buybacks and future debt.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as escalating geopolitical tensions, particularly surrounding potential US tariffs on European countries over Greenland, drive a significant 'risk-off' rotation in the markets. The community is actively discussing gold as a premier safe-haven asset, anticipating continued strong upside as investors seek protection against market instability and potential fiat currency debasement. This robust demand is pushing the metal to new highs amidst broader concerns over the US dollar and global economic conditions.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to recent reports of exceptionally high-grade silver drill results from its Nevada project and a broader surge in precious metals prices. The community is actively discussing continued accumulation by billionaire investor Eric Sprott and the potential for a significant short squeeze, while also noting recent commentary from CEO Diane Garrett regarding the company's capital position. Despite enthusiasm for its vast resources, some caution against its current lack of commercial production amid a rapidly rising valuation.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid significant business developments, including an expanded multi-year, multi-hundred-million-dollar deal with HD Hyundai and prominent features at Davos showcasing its AI platform's efficiency. Community discussion is polarized between excitement over its AI-driven revenue growth and skepticism concerning its high valuation, alongside recent controversial reports about its work with government agencies like ICE. The company's unique position at the intersection of AI, government, and enterprise continues to fuel intense debate on its ethical implications and future growth trajectory.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing a sharp downturn as natural gas prices surge due to "mega bullish" cold weather forecasts and an anticipated "short squeeze" in long natural gas positions. The community is actively debating whether to buy KOLD on its significant dip, anticipating a potential reversal in what many perceive as overbought natural gas. Traders are navigating extreme volatility and the inherent decay of these leveraged ETFs, closely watching for further shifts in weather patterns and market sentiment for this "widowmaker" commodity.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies (AVR) is trending following news of a significant public offering coupled with a strategic private placement where Medtronic agreed to acquire a substantial stake, alongside the initiation of its pivotal PARADIGM trial for the DurAVR heart valve. While some investors are expressing concerns about share dilution, a strong bullish sentiment persists within the community, citing institutional interest and the potential for a major re-rating given the advanced stage of its medical device technology.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending due to recent significant government contract wins, notably with the U.S. Department of Health and Human Services and the U.S. Army, signaling increasing adoption of its enterprise AI solutions within the public sector. The community is actively debating whether these new contracts, combined with its high short interest and new leadership, position the company for a major turnaround despite past financial concerns and ongoing skepticism about its long-term growth trajectory.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending following positive Phase 1 clinical trial data for its eczema drug, soquelitinib, which showed significant efficacy and safety, particularly in treatment-resistant patients. This promising development has fueled speculation about its blockbuster potential and future partnerships, even as the company's recent public offering sparks debate among investors regarding potential dilution versus funding for accelerated pipeline progression. The community is actively discussing the drug's strong profile and the ongoing battle between bulls and bears as the stock experiences substantial volatility.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its highly engaged community champions the "OG meme" narrative of Rage Comics, positioning it as a foundational meme reset for the current market cycle. This dedicated base actively builds an ecosystem with platforms like RageMaker and RageGames, expressing strong conviction and urging fellow enthusiasts to "Return to the Memes" and "Rage On" to reclaim leadership in the meme coin space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lightning Round: Shell is 'just an ok oil company', says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stocks including: Immunitybio, Pan American Silver, KLA Corp, Firefly Aerospace, Shell, and more...

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer

ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label...

ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's What Happened

ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Still a Buy...

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

ImmunityBio plans to resubmit its Anktiva FDA application after new feedback, sharing long-term data that shows high survival and bladder preservation in certain bladder cancer patients.read more...

Best Biotech Stocks To Add to Your Watchlist - January 20th

ImmunityBio, Danaher, Moderna, argenex, Vertex Pharmaceuticals, Abivax, and Recursion Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

ImmunityBio Stock Surges 26% After FDA Outlines Resubmission Path For ANKTIVA

(RTTNews) - ImmunityBio, Inc. (IBRX) shares jumped 25.82%, trading at $6.95, up $1.43, after the company announced it has advanced regulatory discussions with the U.S. Food and Drug Administration on...

Corvus Pharmaceuticals, Immunitybio, Acadia Healthcare And Other Big Stocks Moving Higher On Tuesday

ImmunityBio (NASDAQ:IBRX) Receives "Buy" Rating from D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $24.00 target price on shares of ImmunityBio in a report on Tuesday...

<ul class="summary-bullets"><li>ANKTIVA is an Interleukin-15 (IL-15) receptor agonist that helps develop and activate key cells that work to destroy cancer cells.</li><li>The company presented an overview of the clinical status of its papillary disease program, including more than five years of follow-up data.</li><li>The data demonstrated strong bladder preservation outcomes.</li></ul>ImmunityBio (IBRX) shares rose 6% in pre-market trading on Tuesday after the United States Food and Drug Administration (FDA) outlined a pathway for resubmitting its supplemental biologics license application (sBLA) for ANKTIVA in Bacillus Calmette Guérin (BCG)-unresponsive papillary bladder cancer, without requesting new trials.&nbsp;The company said it recently met with the FDA for a Type B end-of-phase meeting to review data spanning over five years.<h2 class="st-heading-2">The FDA Meeting</h2>During the meeting, ImmunityBio presented more than five years of follow-up data supporting the papillary disease indication. Long-term results, published in The Journal of Urology, showed bladder cancer–specific survival of around 96% at three years, with median survival not yet reached.The data also demonstrated strong bladder preservation outcomes, with cystectomy avoidance rates of 92% at one year and 82% at three years, alongside a safety profile consistent with ANKTIVA’s currently approved use in carcinoma in situ (CIS).Based on these discussions, the FDA recommended that ImmunityBio submit additional information for further evaluation to potentially support a resubmission of the sBLA initially filed in 2025. The Agency did not request any new clinical trials.“We have completed the assembly and analysis of the requested additional information and will submit it within the next 30 days for the Agency’s review,” said Richard Adcock, President and CEO of ImmunityBio.ANKTIVA is an Interleukin-15 (IL-15) receptor agonist. IL-15 is an immune system protein that helps develop and activate key cells that work to destroy cancer cells. It is already commercially available in the U.S. for NMIBC CIS, with or without papillary tumors, and has received approvals in the U.K. and Saudi Arabia, as well as conditional approval in the European Union.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/IBRX">IBRX</a> remained in the ‘extremely bullish’ territory over the past 24 hours, amid ‘extremely high’ message volumes. IBRX was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_704152379c.webp" alt="IBRX.jpg">One user laid out the potential triggers for the stock.<stembedurl>https://stocktwits.com/end2war/message/642249657</stembedurl>Over the past year, the stock has gained 85,% and year-to-date, it has added more than 173%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-rapt-stock-surge-63-in-pre-market-today/cmUuK0vR4aO">Why Did RAPT Stock Surge 63% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing

The company said it recently held end-of-phase talks with the United States Food and Drug Administration on its ANKTIVA application for treatment-resistant papillary bladder cancer.

This FDA Signal Is Powering IBRX Stock's Pre-Market Jump

Equity

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA in BCG-Unresponsive Papillary Bladder Cancer

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA regarding the Companys supplemental...

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Stocktwits

Stocktwits Polls

Investors are buzzing about ANKTIVA's potential to revolutionize cancer treatment, citing existing FDA approval for bladder cancer and upcoming expansions into NSCLC, Glioblastoma, and Head & Neck cancer, promising chemotherapy-free solutions.

Traders anticipate a massive short squeeze, citing over 160 million shares shorted in the last 5 days, increasing cost-to-borrow, record-breaking trading volume, and consistent after-hours strength despite overall market weakness.

Discussions highlight significant Saudi Arabian investments and approvals for cancer treatments, the development of AI-driven drug manufacturing robots expected to reduce costs tenfold, and potential expansion into Canadian and EU markets.

Discussions focus on CEO Dr. Patrick Soon-Shiong's strategic vision, including his engagement with Saudi Arabia, the rollout of AI-driven manufacturing, and anticipated regulatory moves like syncing FDA SBLA resubmission with EU approvals.

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IBRX News

IBRXImmunityBio Inc